Evidence map›Paper›PMID 27289228›Full record

ReviewDrug safety2016

Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Irma Convertino, Alice Capogrosso Sansone, Alessandra Marino, Maria T Galiulo, Stefania Mantarro, Luca Antonioli, Matteo Fornai, Corrado Blandizzi, Marco Tuccori

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Drug safety, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Guideline
  2. Hypothermia as a Presenting Sign of Venlafaxine-Induced Neonatal Abstinence Syndrome in 2 Neonates.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Trends in Drug Tests among Children: A 22-Year Retrospective Analysis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Irma ConvertinoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Alice Capogrosso SansoneDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Alessandra MarinoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Maria T GaliuloDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Stefania MantarroDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Luca AntonioliDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Matteo FornaiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Corrado BlandizziDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Marco TuccoriTuscan Regional Centre for Pharmacovigilance, Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Via Roma, 55, 56126, Pisa, Italy. m.tuccori@ao-pisa.toscana.it.
University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exposure to drugs during pregnancy has the potential to harm offspring. Teratogenic effects are the most feared adverse outcomes in newborns; however, a wide spectrum of less known, usually reversible and often acute, neonatal adverse events can also occur due to drug intake by mothers during pregnancy, particularly in close proximity to delivery. This narrative review is aimed at the description of drugs and drug classes for which licit maternal use in the predelivery period has been associated with neonatal non-teratogenic disorders. For each drug class, epidemiology, clinical features, biological mechanism and management of these adverse reactions have been discussed in detail. Although these adverse reactions have been described mainly for substances used illicitly for recreational purposes, several prescription drugs have also been involved; these include mainly psychotropic medications such as opioids, antidepressants, antiepileptics and antipsychotics. These effects can be partly explained by withdrawal syndromes (defined also as 'neonatal abstinence syndrome') caused by the delivery-related discontinuation of the drug disposition from the mother to the fetus, with symptoms that may include feeding disorders, tremors, irritability, hypotonia/hypertonia, vomiting and persistent crying, occurring a few hours to 1 month after delivery. Otherwise, neonatal neurological and behavioral effects can also be caused by a residual pharmacological effect due to an accumulation of the drug in the blood and tissues of the newborn, with various symptoms related to the toxic effects of the specific drug class, usually developing a few hours after birth. With few exceptions, validated protocols for the assessment and management of withdrawal or residual pharmacological effects of these drugs in neonates are often lacking or incomplete. Spontaneous reporting of these adverse reactions seems limited, although it might represent a useful tool for improving our knowledge about drug-induced neonatal syndromes.

Indexed as

Adaptation, PhysiologicalDrug-Related Side Effects and Adverse ReactionsFemaleHumansInfant, NewbornNeonatal Abstinence SyndromePregnancyPrescription DrugsPsychotropic DrugsPrescription DrugsPsychotropic Drugs

Identifiers

PMID27289228
OpenAlexW2409304735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.